/
NBP
$1.98+$0.34 (+20.73%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$189.7M
116M shares
52-week range
$1.46 – $5.19
14% from low
Exchange
NASDAQ
ADRC
Borrow rate
3.35%
Moderate
Price (6 mo)
Loading chart…
Change$-2.57
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $53.8M | $30.0M | $1.54B | $88.0M | −$10.7M | $4.5M | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $46.4M | $0 | $0 | $0 | $0 |
| Gross profit | $53.8M | $30.0M | $1.54B | $41.6M | −$10.7M | $4.5M | $0 | $0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 47.3% | 100.0% | 100.0% | — | — |
| R&D | $426.0M | $840.4M | $984.7M | $190.3M | $155.5M | $114.4M | $158.9M | $9.0M |
| Operating income | −$455.7M | −$1.46B | $155.6M | −$2.07B | −$366.1M | −$511.2M | −$375.4M | −$13.5M |
| EBITDA | −$431.9M | −$197.3M | $168.3M | −$2.06B | −$51.2M | −$344.3M | −$373.5M | −$13.4M |
| Net income | −$402.8M | −$1.45B | $470.9M | −$2.33B | −$2.51B | −$1.47B | −$162.3M | −$6.6M |
| Net margin | -749.0% | -4826.8% | 30.5% | -2648.7% | 23438.9% | -32674.0% | — | — |
| EPS (diluted) | -6.92 | -25.53 | 6.90 | -30.68 | -30.38 | -17.62 | -4.46 | -0.16 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-3.29 | $-3.29–$-3.29 | 1 |
| 2027 | $0 | $-4.96 | $-4.96–$-4.96 | 1 |
| 2028 | $107M | $-5.30 | $-5.30–$-5.30 | 1 |
| 2029 | $168M | $-5.81 | $-5.81–$-5.81 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.11
Price
$1.98
Implied downside
-95%
Peer comparison
NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
www.novabridge.com- Employees
- 30
- IPO / List date
- Jan 17, 2020
Held by traders on TradeandTell
No one on the platform currently holds NBP.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 272,412 | $670.1K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NBP yet.